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Background
Methotrexate (MTX) is an efficacious drug in juvenile
idiopathic arthritis (JIA). If JIA patients are unresponsive
to MTX, effective combination treatment with biologi-
cals is required to prevent joint damage.
Aim
To develop a prediction model to identify MTX non-
responders according to the American College of Rheu-
matology 70 criteria during the first year of treatment.
Methods
Data was collected on 183 JIA patients. Clinical vari-
ables and single nucleotide polymorphisms (SNPs) in
genes involved in the mechanism of action of MTX
were determined at baseline. Using multivariate back-
ward logistic regression, these variables were used to
construct a prediction model for MTX non-response,
whose diagnostic accuracy was evaluated. The model
was subsequently validated in a cohort of 104 JIA
patients.
Results
The prediction model included: erythrocyte sedimenta-
tion rate and SNPs in genes coding for methionine
synthase reductase, multidrug resistance 1, multidrug
resistance protein 1 and proton-coupled folate trans-
porter. The area under the receiver operating charac-
teristics curve (AUROC) was 0.73 (95%CI: 0.64-0.81).
The prediction model was transformed into a total risk
s c o r e( r a n g e0t o1 1 ) .A tac u t - o f fs c o r eo f≥3, sensitiv-
ity was 78%, specificity 49%, positive predictive value
was 83% and negative predictive value 41%. In the
validation cohort, the AUROC was 0.65 (95%CI: 0.54-
0.77).
Conclusion
The prediction model we developed and validated com-
bines clinical and genetic variables to identify JIA
patients not responding to MTX treatment. This model
could assist clinicians in making individualized treat-
ment decisions.
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